Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 13, 2020 16:01 ET | Source: Lumos Pharma, Inc.

Lumos Pharma Reports Second Quarter 2020 Results and Provides Update on Clinical and Corporate Activities

Lumos Pharma sells Priority Review Voucher (PRV), valued at $100 million - Lumos Pharma to receive $60 million for its 60% interest in PRVLumos Pharma reaffirms its expectation of the initiation of...
July 28, 2020 16:01 ET | Source: Lumos Pharma, Inc.

Lumos Pharma to Report Second Quarter 2020 Financial Results and Host a Conference Call on August 13, 2020

AUSTIN, Texas, July 28, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will...
July 27, 2020 16:05 ET | Source: Lumos Pharma, Inc.

Lumos Pharma Announces Sale of Priority Review Voucher

AUSTIN, Texas, July 27, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced that it has...
May 28, 2020 16:01 ET | Source: Lumos Pharma, Inc.

Lumos Pharma Reports First Quarter 2020 Results and Provides Update on Clinical and Corporate Activities

- Lumos Pharma expects to initiate its Phase 2b LUM-201 trial in Pediatric Growth Hormone Deficiency (PGHD) prior to the end of 2020 - Additional non-dilutive funds expected from anticipated...
May 27, 2020 16:27 ET | Source: Lumos Pharma, Inc.

Lumos Pharma to Participate in the Jefferies 2020 Healthcare Conference

AUSTIN, Texas, May 27, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced that the...
May 26, 2020 10:36 ET | Source: Lumos Pharma, Inc.

Lumos Pharma to Report First Quarter 2020 Financial Results and Host a Conference Call on May 28, 2020

AUSTIN, Texas, May 26, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report...
April 24, 2020 08:00 ET | Source: Lumos Pharma, Inc.

Lumos Pharma Hires Biotech Veteran Aaron Schuchart as Chief Business Officer

AUSTIN, Texas, April 24, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that Aaron...
April 02, 2020 16:05 ET | Source: Lumos Pharma, Inc.

Lumos Pharma Promotes John C. McKew, PhD to Chief Operating Officer and Chief Scientific Officer

AUSTIN, Texas, April 02, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced the promotion of...
March 30, 2020 08:00 ET | Source: NewLink Genetics Corporation

Lumos Pharma Appoints Joseph S. McCracken, DVM, MS to Board of Directors Rick Hawkins, CEO, appointed Chairman of the Board

AUSTIN, Texas, March 30, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, has announced the...
March 18, 2020 08:00 ET | Source: NewLink Genetics Corporation; Lumos Pharma, Inc.

NewLink Genetics Stockholders Approve Merger with Lumos Pharma

- Combined company, Lumos Pharma, Inc., to trade on Nasdaq under the stock symbol “LUMO” - Phase 2b trial expected to be initiated mid-2020 evaluating oral therapeutic candidate LUM-201 (ibutamoren)...